Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Novo Nordisk reported the results from the STEP 1 extension trial on the impact of treatment withdrawal, which found that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss
During the session, they addressed seven specific questions: What are the key metabolic benefits of combining SGLT2is with GLP1-RAs compared to using each therapy alone in individuals with T2D
Drug combinations Combinations of agents that target cysteine metabolism have also been explored
To confirm whether Med14 was an integral link between GLP-1 drugs and ultimate changes in gene expression and pancreatic beta cell behavior, the researchers decided to mutate Med14, making the protein resistant to phosphorylation
